QF
BCRX icon

QVT Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

QVT Financial’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,358,097
Closed -$14M – 85
2015
Q4 		$14M Hold
1,358,097
– – 0.79% 35
2015
Q3 		$15.5M Buy
1,358,097
+186,200
+16% +$2.48M 0.53% 34
2015
Q2 		$17.5M Sell
1,171,897
-137,485
-10% -$1.56M 0.26% 41
2015
Q1 		$11.8M Buy
1,309,382
+63,100
+5% +$653K 0.66% 42
2014
Q4 		$15.2M Buy
1,246,282
+520,548
+72% +$5.75M 0.76% 37
2014
Q3 		$7.1M Hold
725,734
– – 0.37% 64
2014
Q2 		$9.25M Buy
725,734
+200,000
+38% +$1.95M 0.5% 58
2014
Q1 		$5.56M Hold
525,734
– – 0.32% 64
2013
Q4 		$4M Buy
525,734
+318,700
+154% +$2.02M 0.23% 64
2013
Q3 		$1.51M Buy
+207,034
New +$1.05M 0.1% 68

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

QVT Financial's BCRX Position: Q1 2016 in Review

QVT Financial sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2016, closing a stake of 1,358,097 shares — an estimated $14M sold.

QVT Financial first reported a position in BCRX in Q3 2013 and held it in 10 quarters. The position peaked at $17.5M in Q2 2015. 109 funds tracked by Wall St. Rank hold BCRX as of Q1 2016.

  • QVT Financial reported no remaining BioCryst Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • QVT Financial sold 1,358,097 BioCryst Pharmaceuticals shares in Q1 2016, an estimated $14M.
  • QVT Financial first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 10 quarters.
  • QVT Financial's BioCryst Pharmaceuticals position peaked at $17.5M in Q2 2015.
  • 109 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2016.

Based on QVT Financial's 13F filing for Q1 2016, filed 16 May 2016.